New quarterly report expected Apr 22, 2026. Report will refresh after results.
M
Medpace Holdings, Inc.
MEDP · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
The Backlog Doesn't Lie: Medpace's GLP-1 Tide Is Turning
The market is debating whether the Q4 cancellation spike is noise or signal — but the sharper question is why backlog grew only four percent on record new awards, which means the cancellations were large enough to nearly neutralize a historically strong win year, and that math deserves more respect than the consensus is giving it.
Flowly Score
Apr 16 Close
+47%$515.65
Fair Value
$760.00
70
Strongat $515.65
Business Strength8/10
Medpace has built one of the most defensible niches in healthcare services — mid-trial switching costs are catastrophic for asset-light biotechs, creating an embedded CRO relationship that functions more like a partnership than a vendor contract. The governance wrinkles (related-party lease, combined Chairman-CEO) are real friction that prevent a 9, but the underlying business quality and founder discipline are exceptional.
Financial Resilience8/10
Customer-financed, asset-light, and generating cash well ahead of reported earnings — this is a business whose balance sheet flatters without lying. The near-doubling of debt and cash drawdown in Q4 reflects buyback aggression, not operational stress, and the FCF conversion trajectory over five years is the cleanest signal: the machine doesn't need feeding to grow.
Growth & Trajectory6/10
The Q4 cancellation spike — widespread, metabolic-skewed, driven by compound failures — compressed backlog growth to just over four percent despite record new business awards, which is the ledger's honest admission that the GLP-1 wave is cresting rather than accelerating. The deceleration to high-single-digit growth in 2026 is real, not optical, and the book-to-bill barely clearing 1x signals that near-term momentum has genuinely cooled.
Valuation7/10at $478.54
At current prices, the neutral DCF scenario implies substantial upside and even the pessimistic case offers meaningful cushion — remarkable for a business trading at elevated multiples — because the asset-light compounding and share count shrinkage are understated in headline earnings metrics. The multiple feels rich until you price in that ROIC has run consistently above forty percent on almost no invested capital, at which point the question is whether that ROIC is sustainable or a cycle artifact.
Risk5/10
The backlog signal is the most concrete near-term risk: if Q4 cancellations are a one-quarter anomaly, the business is cheap; if they're the leading edge of a biotech funding contraction, the multiple compresses before earnings do, which is a painful sequence for growth-premium stocks. Layered on top is the metabolic concentration risk, FDA structural disruption from political turbulence, and key-man exposure to a founder whose departure would be genuinely destabilizing — a cluster of risks that are individually manageable but collectively real.
Medpace is a genuinely exceptional business — high-ROIC, asset-light, defended by switching costs that are measured in clinical program survival rather than dollars — trading at multiples that would only make sense if the GLP-1 tailwind continues at full velocity. The neutral DCF suggests meaningful undervaluation, but that scenario requires mid-teens growth reaccelerating out of a year where management guided to barely half that rate. The price you're paying today embeds an optimism about reacceleration that the company's own backlog data doesn't yet support. The direction of travel for this business is structurally positive over a five-year horizon. As biotech programs grow more complex — adaptive designs, combination therapies, increasingly demanding FDA safety requirements — the premium on a CRO that gets submissions right on the first pass compounds. Medpace's decision to stay narrow while competitors built sprawling global platforms looks more prescient each cycle, not less. AI will eventually restructure trial design economics, and Troendle's candor about 2026 being an investment year before benefits materialize is the kind of honest framing that builds long-term credibility. The single biggest risk is not AI disruption or competitive pressure from the large CROs — it is the biotech funding cycle, specifically whether the Q4 cancellation breadth is the beginning of a drawdown in small-biotech capital that systematically shrinks Medpace's addressable pipeline. Their client base doesn't have pharma mega-cap anchors to smooth revenue through funding troughs; when venture dries up, trial starts pause, and Medpace's utilization drops faster than a large CRO's. That vulnerability is structural, not fixable, and it's the reason the risk score anchors the overall thesis.